What this is
- How it works
- How it works isn't classified yet
- Tested for
- Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
- Main trialPhase 1
- “The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.”In the company’s words, NCT02926690 on ClinicalTrials.gov
Other drugs for Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up1
- Sep 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Sep 2027 | Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026